June 15, 2020 / 12:19 PM / a month ago

BRIEF-Kalytera Announces Data Showing R-107 Increases Survival In Murine Study Of Chlorine Inhalational Lung Injury

June 15 (Reuters) - Kalytera Therapeutics Inc:

* KALYTERA ANNOUNCES DATA DEMONSTRATING THAT R-107 PREVENTS TISSUE DAMAGE AND INCREASES SURVIVAL IN A MURINE STUDY OF CHLORINE INHALATIONAL LUNG INJURY

* KALYTERA THERAPEUTICS INC - PLANNED IND SUBMISSION TO AUSTRALIAN TGA, U.S FDA FOR A PHASE 1 CLINICAL STUDY OF R-107 IN HEALTHY MIDDLE-AGED VOLUNTEERS

* KALYTERA - PHASE 2, PHASE 3 HUMAN CLINICAL STUDIES OF R-107 WILL NOT BE REQUIRED FOR FDA APPROVAL FOR TREATMENT OF CILI UNDER FDA’S “ANIMAL RULE” (21 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below